Recent times have witnessed an upsurge in the incidence of neurodegenerative disorders
such as Alzheimer's disease, Parkinson's disease, Huntington's disease, Prion disease, and …

Therapies directed toward the central nervous system remain difficult to translate into
improved clinical outcomes. This is largely due to the blood–brain barrier (BBB), arguably …

Research into treatments for diseases of the CNS has made impressive strides in the past
few decades, but therapeutic options are limited for many patients with CNS disorders …

Neurodegenerative disorders including Alzheimer's and Parkinson's diseases, amyotrophic
lateral sclerosis, and stroke are rapidly increasing as population ages. The field of …

In recent decades, research scientists, molecular biologists, and pharmacologists have
placed a strong emphasis on cutting-edge nanostructured materials technologies to …

Nanotechnology employs engineered materials or devices that interact with biological
systems at a molecular level and could revolutionize the treatment of neurodegenerative …

The efficacy, cellular uptake and specific transport of drugs and/or imaging agents to target
organs, tissues and cells are common issues in the diagnosis and treatment of different …

Neurodegenerative disorders (NDs) are highly prevalent among the aging population. It
affects primarily the central nervous system (CNS) but the effects are also observed in the …

Due to limitations posed by the restrictive blood–brain barrier, conventional drug delivery
systems do not provide adequate cyto‐architecture restoration and connection patterns that …

Neurodegeneration is characterized by progressive, disabling, and incurable neurological
disorders with the massive loss of specific neurons. As one of the most promising potential …